Trials / Completed
CompletedNCT01196728
Single-centre, Randomised, Double-blind, Placebo-controlled, Four-way Crossover Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Single Doses of CM3.1-AC100 in Patients With Type 2 Diabetes
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (estimated)
- Sponsor
- CellMed AG, a subsidiary of BTG plc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to assess the safety and tolerability of the Glucagon-like peptide-1 (GLP-1) peptide analogue CM3.1-AC100 after single subcutaneous (sc) doses in patients with T2DM.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CM3.1-AC100 | SAD study with single ascending subcutaneous doses |
Timeline
- Start date
- 2010-09-01
- Primary completion
- 2010-11-01
- Completion
- 2010-11-01
- First posted
- 2010-09-08
- Last updated
- 2010-12-06
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT01196728. Inclusion in this directory is not an endorsement.